Ultrasound Enhanced Thrombolysis: Applications in Acute Cerebral Ischemia

Georgios Tsivgoulis, M.D., Andrei V. Alexandrov, M.D.

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL

Intravenous tissue plasminogen activator (TPA) improves patient chances to recover from stroke by inducing mostly partial recanalization of large intracranial thrombi. TPA activity can be enhanced with ultrasound including 2 MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. The international multi-center CLOTBUST trial showed that ultrasound enhances thrombolytic activity of a drug in humans thereby confirming multidisciplinary experimental research conducted worldwide for the past 30 years.

In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 hours after TPA bolus occurred in 25% of patients treated with TPA+TCD compared to 8% who received TPA alone (p=0.02). Complete clearance of a thrombus and dramatic recovery of brain functions during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the Target CLOTBUST group resulted in a trend of 13% more patients achieving favorable outcome at 3 months, subject for a pivotal trial. However, different results were achieved in a small TRUMBI trial and another study that used Transcranial Color-Coded Duplex Sonography (TCCD). Adverse bio-effects of mid-KHz (300) ultrasound promote bleeding, including brain areas not-affected by ischemia while exposure to multi-frequency / multi-element duplex ultrasound resulted in a trend towards higher risk of hemorrhagic transformations.

To further enhance the ability of TPA to break up thrombi, current ongoing clinical trials include phase II studies of a single beam 2 MHz TCD with perflutren-lipid microspheres. Enhancement of intra-arterial TPA delivery is being clinically tested with 1.7-2.1 MHz pulsed wave ultrasound (EKOS catheter). Multi-national dose escalation studies of microspheres and the development of an operator independent ultrasound device are underway.

J Clin Neurol 3(1):1-8, 2007

Key Words : TPA, Transcranial Doppler; Stroke, Thrombolysis, Outcomes

INTRODUCTION

Unlike thrombolysis for myocardial ischemia, the pilot clinical studies of thrombolysis for ischemic stroke did not document dramatic, “Lazarus” or “on the table” clinical recovery during treatment.1-3 Subsequent pivotal trials of TPA have not reported any differences between the groups at 2 and 24 hours post treatment in the pre-specified end-points.4-7 However, a post-hoc analysis of the NINDS trial8 showed that by 24 hours, 27% of TPA-treated patients improved by ≥10 points on the National Institutes of Health Stroke Scale (NIHSS) or resolved their neurological deficit completely compared
to 12% in the placebo group ($p=0.002$). Therefore, some patients may have experienced early clinical recovery presumably due to fast thrombus dissolution, but the overall number of these events was low.

Early clinical improvement after stroke usually occurs after arterial recanalization. A recent meta-analysis confirmed the recanalization hypothesis by showing that the occurrence of recanalization is associated with a 4- to 5-fold increase in the odds of good final functional outcome and a 4- to 5-fold reduction in the odds of death. These results lend strong support to the use of restoration of vessel patency as a surrogate end point in phase II trials of pharmacological recanalization agents and in trials comparing novel to existing predicate recanalization devices in acute ischemic stroke. Since early recanalization can lead to dramatic recovery, any additional enhancement of TPA-associated thrombus dissolution can possibly produce even higher early recovery rates among patients with ischemic stroke.

The ability of an ultrasonic mechanical pressure wave to enhance thrombolysis has been documented in 1970’s, and confirmed by many in experimental models. The likely mechanism that emerged from these in vitro and in vivo experiments is the ability of ultrasound to agitate flow around and through the thrombus thus delivering more TPA to target binding sites. In stroke patients, ultrasound can promote TPA delivery to the areas with stagnant flow near occlusion.

Although low kilohertz frequencies better potentiate TPA effects, these systems are not available for clinical practice due to safety concerns and inability to image vasculature with this frequency/wavelength range. Meanwhile, 1-2.2 MHz frequencies can also enhance TPA-induced thrombus dissolution utilizing different mechanisms such as fluid streaming around clot surface, dis-aggregation of fibrin fibers, and creating more binding sites for TPA without heating or cavitation. This frequency range is safely used for diagnostic ultrasound examinations.

Portable diagnostic 2 MHz TCD equipment can be used the emergency room to continuously monitor TPA infusion is acute ischemic stroke patients. With prior training and experience in interpretation of TCD, this test, particularly in combination with urgent carotid/vertebral duplex scanning, can yield high degrees of accuracy for detection and localization of arterial occlusion as well as assessment of recanalization at bedside. In addition, TCD can be complementary to other imaging modalities such as CTA by showing real-time flow findings (real-time embolization, collateralization of flow with extracranial internal carotid artery disease, alternating flow signals indicative of steal phenomenon). Finally, real time flow findings during TCD-monitoring has been shown to be associated with long-term functional outcome.

Once abnormal residual flow signals are identified, an ultrasound beam can be steadily focused at presumed intra-cranial thrombus location, and arterial recanalization can be monitored in real time. When intravenous TPA infusion was continuously monitored with 2 MHz TCD, we have observed early recanalization and dramatic recovery rates higher than expected. This non-randomized study of patients treated with TPA suggested potential therapeutic effect of TCD and led to a prospective randomized clinical trial.

The CLOTBUST Trial

The CLOTBUST (Combined Lysis of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic TPA, Fig. 1) was a phase II clinical randomized multi-center international trial with centers in Houston, Barcelona, Edmonton, Calgary. It had pre-specified safety and signal of efficacy end-points and a pre-determined sample size of 63 patients per group. All enrolled patients had an acute ischemic stroke, and were treated with a standard 0.9 mg/kg dose of intravenous TPA therapy within 3 hours of symptom onset. All patients also had MCA occlusions on pre-treatment TCD. They were randomized (1:1) to continuous TCD monitoring (Target) or placebo monitoring (Control).

Safety end-point was symptomatic brain hemorrhage (sICH) causing worsening of the neurological deficit by 4 or more NIH Stroke Scale (NIHSS) points. Primary combined activity end-point was complete recanalization on TCD or dramatic clinical recovery by the total NIHSS score ≤ 3 points, or improvement by ≥ 10
Tsivgoulis G and Alexandrov AV. Ultrasound Enhanced Thrombolysis for Stroke

Table 1. Reported controlled clinical trials of ultrasound-enhanced systemic thrombolysis for acute ischemic stroke.27,28,34 The Table was reproduced with permission from Andrei Alexandrov (n; total number of patients enrolled in both control and target groups, Transducer; images of actual sources of ultrasound and their size relative to patient head, Tissues exposed; images of beam paths as ultrasound propagates through the brain, sICH; percent rates of symptomatic intracranial hemorrhages, CR; complete recanalization at the end of monitoring period, mRS 0-1; modified Rankin scores at 3 months follow-up (? -percent or actual number not reported in the original publication34).

| Trial         | Transducer | Tissues Exposed | sICH | CR  | mRS 0-1         |
|---------------|------------|-----------------|------|-----|----------------|
| CLOTBUST      | n = 126    | 2 MHz single beam | 4.8% | 38% | 42% completed  |
| Eggers et al. | n = 25     | 2-4 MHz         | 18%  | 27% | 27% no pre-determined sample size |
| TRUMBI        | n = 26     | 300 KHz multi-  | 36%  | <22%| ? terminated   |

NIHSS points within 2 hours after TPA bolus. Clinical investigators were blinded to group assignment (active or sham monitoring) done by sonographers.

All projected 126 patients received TPA and were randomized 1:1 to target (median pre-treatment NIHSS 16 points) or control (NIHSS 17 points). Age, occlusion location on TCD and time to TPA bolus were similar between groups. sICH occurred in 4.8% Target and 4.8% Controls. Primary end-point was achieved by 31 (49%, Target) vs 19 (30%, Control), p=0.03. At 3 months, 42% Target and 29% Control patients achieved favorable outcomes (mRS 0-1 points), NS. This trend indicates feasibility of a pivotal phase III clinical trial that, at 274 patients per group, would be properly powered to detect this difference in outcomes at 3 months.39

**Other Clinical Trials**

Transcranial duplex technology was recently tested in a smaller randomized clinical trial.30 Duplex transducers are different from the ones used in CLOTBUST since they generate multiple small beams at dual emitting frequencies, one for Doppler and one for gray scale imaging (Fig. 1). One of major limitations of this technology that there are no reliable head frames for transducer fixation, and most studies are to be carried out hand-held. In addition, the mechanical index of these scanners is higher than TCD and no dose escalation study was performed to determine how little ultrasound is needs to enhance thrombolysis without safety concerns that would be outlined below.

Eggers et al. evaluated 25 patients (11 Target TPA+duplex monitoring, 14 Controls TPA alone) and reported a trend in the Target group towards higher
Table 1. Reported controlled clinical trials of microsphere-potentiated ultrasound-enhanced systemic thrombolysis for acute ischemic stroke using Tran cranial Doppler (TCD) and Transcranial Color-Coded (TCCD) Ultrasonography

| Trial            | F | ECA            | Design                                      | R  | REC** | AsxICH** | sICH** | Outcome at 3 months |
|------------------|---|----------------|---------------------------------------------|----|-------|----------|--------|---------------------|
| **TCD**          |    |                |                                             |    |       |          |        |                     |
| Molina et al.    | 2 MHz | galactose-based | US/MS/tPA (n=38) vs. US/tPA (n=37)          | N  | 71%   | 23%      | 3%     | 56% (mRS 0-2)       |
| Alexandrov et al. | 2 MHz | perfultren-lipid | US/MS/tPA (n=12) vs. US/tPA (n=3)          | Y  | 42%   | 25%      | 0%     | 40% (mRS 0-1)       |
| **TCCD**         |    |                |                                             |    |       |          |        |                     |
| Larrue et al.    | 2 MHz* | galactose-based | US/MS/tPA (n=9) vs. TPA (n=11)             | Y  | 48%   | 78%      | 0%     | NA                  |
| Perren et al.    | 2 MHz* | phospholipid-encapsulated sulphur hexafluoride | US/MS/tPA (n=11) vs. tPA (n=15)          | N  | 64%   | NA       | 9%     | NA                  |

US; Continuous Ultrasound Monitoring, MS; microspheres, tPA; tissue plasminogen activator, R; Randomization, REC; recanalization at the end of TCD monitoring, sICH; symptomatic intracranial hemorrhage, AsxICH; asymptomatic intracranial hemorrhage, mRS; modified Rankin Scale, NA; not available. *patients received monitoring with a pulsed wave 2 MHz phased array Doppler and intermittent exposure to dual frequency duplex. **in the active treatment group (microsphere-potentiated ultrasound-enhanced systemic) thrombolysis.***at three months

Furthermore, different experimental strategies are being tested in an extended time window for acute stroke treatment, and continuous exposure to ultrasound may find its application while patient may be receiving other agents such as GP IIb-IIIa antagonists or direct thrombin inhibitors or awaits intra-arterial procedures.

Ultrasound transducers were also incorporated into a catheter for intra-arterial delivery of a thrombolytic drug (EKOS Corporation). This intra-arterial device uses 1.7 - 2.1 MHz pulsed wave ultrasound with the emitting power of 400 mW, parameters similar to extracranially applied tran cranial Doppler. The EKOS catheter is now being tested in phase II-III Interventional Management of Stroke (IMS) trials.

Therapeutic, i.e. non-imaging ultrasound has been tested in the TRanscranial low-frequency Ultrasound-Mediated thrombolysis in Brain Ischemia (TRUMBI) trial. First, the investigators used a very low KHz system (<40 KHz) that produced intolerable tinnitus and was withdrawn from clinical testing (Daffertshofer M, unpublished data). It was replaced by a mid KHz system operating at 300 KHz (Fig. 1). The trial was terminated after 26 patients were enrolled with a 36% rate of recanalization rates, more hemorrhagic transformations (18% sICH rate), and better outcomes at 3 months compared to patients who received TPA alone. This study did not have a pre-determined sample size, and the results may be affected by a small number of patients enrolled. More studies are needed to evaluate the potential of transcranial duplex technology to enhance thrombolysis.

The same group and others reported provocative findings that patients who are not eligible for systemic TPA therapy may potentially benefit from continuous monitoring with ultrasound alone since, hypothetically, ultrasound may help facilitate the endogenous thrombolytic process that leads to spontaneous recanalizations in acute stroke patients. It is unclear if only partial recanalization can be induced by ultrasound alone, and if this exposure would result in a significant difference at 3 months justifying a large clinical trial. In any case, there is no clear data regarding the benefit of ultrasound monitoring without TPA and TPA treatment should not be substituted with ultrasound alone in patients otherwise eligible for thrombolytic therapy within 3 hours of symptom onset.
symptomatic hemorrhage in the Target group and no signal of efficacy on early recanalization or clinical outcomes at 3 months.\textsuperscript{36} The trial demonstrated adverse bio-effects of mid-KHz ultrasound that promote bleeding, including brain areas not-affected by ischemia.\textsuperscript{36} Further research should determine if “standing” pressure waves and endothelial disruption may cause these adverse effects. If confirmed \textit{in vivo} models, this will have implications on design of future KHz-based systems.

**Microspheres-potentiated Ultrasound-enhanced Thrombolysis**

Experimental data have suggested that ultrasound-enhanced thrombolysis can be further amplified by adding gaseous microspheres,\textsuperscript{37-39} safe ultrasound contrast agents, are micron-sized lipid shells that when exposed to ultrasound, expand and produce stable cavitation with stronger reflected echoes. This is used to generate ultrasound images with better resolution. At the same time, microspheres agitate fluid where they are released by ultrasound and this is useful in drug delivery and mechanical “grinding” of a thrombus. In fact, microspheres have their own ability to lyse thrombi without a lytic drug.\textsuperscript{37}

Several studies have been reported with different types of commercially available microspheres\textsuperscript{40-43} (Table). Molina et al pioneered this approach in stroke patients and reported the largest study to date that compared the CLOTBUST Target arm to the CLOTBUST Target insonation protocol combined with Levovist air microspheres (Schering AG).\textsuperscript{40} Investigators demonstrated that at 2 hours after TPA bolus the TPA+TCD+Leovist group achieved a 55\% sustained recanalization rate compared to 38\% in the TPA+TCD group of the CLOTBUST trial. The safety and feasibility of infusion of a new and more stable C\textsubscript{3}F\textsubscript{8} perflutren-lipid microspheres in patients treated with ultrasound-enhanced thrombolysis has recently been reported in a small phase IIa randomized clinical trial.\textsuperscript{41} Interestingly, in 75\% of patients, $\mu$S permeated to areas with no pre-treatment residual flow, and in 83\%, residual flow velocity improved at median of 30 min from start of $\mu$S infusion (range 30 s-120 min) by median of 17 cm/s, or 118\% above pre-treatment values (Fig. 2).

Larrue et al recently randomized patients with acute (<3 hours) middle cerebral artery main stem occlusion as demonstrated by CT or MR angiography to either transcranial duplex ultrasound continuous monitoring combined with intravenous galactose-based microspheres and rt-PA (combined treatment group), or rt-PA alone (control group).\textsuperscript{43} Their trial was prematurely discontinued on the basis of safety reasons since a high rate of asymptomatic intracerebral hemorrhage was demonstrated on gradient-echo MRI in the combined treatment group (78\%). However, none of the intracerebral hemorrhages was symptomatic and the fact that asymptomatic hemorrhagic transformation in the setting of acute cerebral ischemia has not been associated with poor outcome both in the NINDS\textsuperscript{44} and the ECASS trial\textsuperscript{45} should be taken into account when interpreting the results of the former
study. It is further unclear why data safety monitoring board was not appointed for this study and why a dose de-escalation decision was not made (i.e. reduce time of exposure to ultrasound or reduce the dose of microspheres). In its current design, the study does not allow to decide whether excessive hemorrhagic transformation rate was attributed to duplex ultrasound or microspheres since controls received just TPA and no ultrasound.

Finally, Perren et al studied the safety and feasibility of TCCD ultrasound monitoring combined with a second generation, phospholipid encapsulated sulphur hexafluoride microsphere (SonoVue) and intravenous systemic thrombolysis in patients with acute middle cerebral artery occlusion. Patients who received Microsphere-potentiated Ultrasound-enhanced Thrombolysis seemed to fare better in terms of improvement in NIHSS-score and sustained a more marked improvement in their residual blood flow in comparison to patients treated only with ultrasound-enhanced thrombolysis.42

**Future Directions**

Currently, an international multi-center controlled TUCSON trial of a new and more stable perfultren-lipid microspheres (MRX 801, www.imarx.com) is underway.46 A total of 72 patients with acute intracranial arterial occlusion as demonstrated by CT or MR angiography will be randomized to Microspheres-potentiated Ultrasound-enhanced Thrombolysis (4 groups with increasing doses of perfultren-lipid microspheres) versus TPA treatment alone.

Microspheres offer a mechanical way to amplify stroke therapies, and can be developed as a new kind of drugs or devices to augment brain perfusion, drug and nutrient delivery within the existing and at an extended time window. One problem on the way to develop ultrasound and microsphere assisted stroke therapies is the need of an experienced sonographer to find intracranial thrombus, and expose its surface to residual flow in order to lodge more TPA and agitate stagnant flow. Personnel with these skills are lacking in most emergency centers. Future studies will focus on the development of an operator-independent ultrasound device that can be used by existing medical personnel regardless of their experience in diagnostic ultrasound.

**REFERENCES**

1. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. *Ann Neurol* 1992;32:78-86.
2. Brott TG, Haley EC, Levy DE, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. Part I pilot study of tissue plasminogen activator administered within 90 minutes. *Stroke* 1992;23:632-640.
3. Haley EC, Levy DE, Brott TG, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part II pilot study of tissue plasminogen activator administered 91-180 minutes from onset. *Stroke* 1992;23:641-645.
4. The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995;333:1581-1587.
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke: the European Cooperative Acute Stroke Study. *JAMA* 1995;274:1017-1025.
6. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. *Lancet* 1998;352:1245-1251.
7. Hacke W, Donnan G, Fieschi C, Kaste M, vom Kummer R, Broderick JP, et al. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet* 2004;363:768-774.
8. Haley EC, Lewandowski C, Tilley BC. Myths regarding NINDS rt-PA Stroke Trial: setting the record straight. *Ann Emerg Med* 1997;30:676-682.
9. Demchuk AM, Felberg RA, Alexandrov AV. Clinical recovery from acute ischemic stroke after early reperfusion of the brain with intravenous thrombolysis. *N Engl J Med* 1999;340:894-895.
10. Grotta JC, Alexandrov AV. TPA-associated reperfusion in acute ischemic stroke demonstrated by SPECT. *Stroke* 1998;29:429-432.
rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab 1998;18:1298-1307.

12. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289-298.

13. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967-973.

14. Trubstein R, Bernard HR, Etzel F, Sobbe A, Cremer A, Stumpff U. Thrombolysis by ultrasound. Clin Sci Mol Med 1976;51:697-698.

15. Tachibana K, Tachibana S. Ultrasonic vibration for boosting fibrinolytic effects of urokinase in vivo. Thromb Haemost 1981;46:211[abstract].

16. Lauer CG, Burge R, Tang DB, Bass BG, Gomez ER, Alving BM. Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis. Circulation 1992;86:1257-1264.

17. Kimura M, Iijima S, Kobayashi K, Furuhata H. Evaluation of the thrombolytic effect of tissue-type plasminogen activator with ultrasound irradiation: in vitro experiment involving assay of the fibrin degradation products from the clot. Biol Pharm Bull 1994;17:126-130.

18. Akiyama M, Ishibashi T, Yamada T, Furuhata H. Low-frequency ultrasound penetrates the cranium and enhances thrombolysis in vitro. Neurosurgery 1998;43:828-832.

19. Suchkova V, Siddiqi FN, Carstensen EL, Dalecki D, Child S, Francis CW. Enhancement of fibrinolysis with 40 kHz ultrasound. Circulation 1998;98:1030-1035.

20. Behrens S, Daffertshoffer M, Spiegel D, Hennerici M. Low-frequency, low-intensity ultrasound accelerates thrombolysis through the skull. Ultrasound Med Biol 1999;25:269-273.

21. Spengos K, Behrens S, Daffertshoffer M, Dempflle CE, Hennerici M. Acceleration of thrombolysis with ultrasound through the cranium in a flow model. Ultrasound Med Biol 2000;26:889-895.

22. Behrens S, Spengos K, Daffertshoffer M, Schroeck H, Dempflle CE, Hennerici M. Transcranial ultrasound-improved thrombolysis: diagnostic versus therapeutic ultrasound. Ultrasound Med Biol 2001;27:1683-1689.

23. Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood 1993;81:2636-2643.

24. Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin WS, et al. High rate of complete recanalization and dramatic clinical recovery during TPA infusio when continuously monitored by 2 MHz transcranial Doppler monitoring. Stroke 2000;31:610-614.

25. Chernyshev OY, Garami Z, Calleja S, Song J, Campbell MS, Noser EA, et al. The yield and accuracy of urgent combined carotid-transcranial ultrasound testing in acute cerebral ischemia. Stroke 2005;36:32-37.

26. Tsivgoulis G, Sharma VK, Lao AY, Malkoff MD, Alexandrov AV. Validation of Transcranial Doppler With Computed Tomography Angiography in Acute Cerebral Ischemia. Stroke 2007;38.[Epub ahead of print]

27. Kim YS, Meyer JS, Garami Z, Molina CA, Pavlovic AM, Alexandrov AV. Flow diversion in transcranial Doppler ultrasound is associated with better improvement in patients with acute middle cerebral artery occlusion. Cerebrovasc Dis 2006;21:74-78.

28. Kim YS, Garami Z, Mikulik R, Molina CA, Alexandrov AV. CLOTBUST Collaborators. Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke 2005;36:869-871.

29. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-2178.

30. Eggers J, Koch B, Meyer K, Konig I, Seidel G. Effect of ultrasound on thrombolysis of middle cerebral artery occlusion. Ann Neurol 2005;3:797-800.

31. Eggers J, Seidel G, Koch B, Konig IR. Sonothrombolysis in acute ischemic stroke for patients ineligible for rt-PA. Neurology 2005;64:1052-1054.

32. Cintas P, Le Traon AP, Larrue V. High rate of recanalization of middle cerebral artery occlusion during 2 MHz transcranial color-coded Doppler continuous monitoring without thrombolytic drug. Stroke 2002;33:626-628.

33. Skoloudik D, Bar M, Hradilek P, Vaclavik D, Skoda O. Safety and efficacy of thrombopripsy - acceleration of thrombolysis by TCCS. CD-ROM Proceedings of the NSRG 2003 Meeting, Germany.

34. The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke 2004;35:904-912.

35. Daffertshoffer M, Hennerici M. Ultrasound in the treatment of ischaemic stroke. Lancet Neurology 2003;2:283-90.

36. Daffertshöfer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator. Stroke 2005;36:1441-1446.

37. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipd-coated microbubbles. Adv Drug Deliv Rev 2004;56:1291-1314.

38. Culp WC, Porter TR, McCowan TC, Robertson PK, James...
CA, Matchett WJ, et al. Microbubble-augmented ultrasound declotting of thrombosed arteriovenous dialysis grafts in dogs. *J Vasc Interv Radiol* 2003;14:343-347.

39. Culp WC, Porter TR, Lowery J, Xie F, Roberson PK, Marky L. Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine. *Stroke* 2004;35:2407-2411.

40. Molina CA, Ribo M, Arenillas J, Rubiera M, Montaner J, Santamarina E, et al. Microbubbles administration accelerates clot lysis during continuous 2 MHz ultrasound monitoring in stroke patients treated with intravenous tPA. *Stroke* 2005;37:425-429.

41. Alexandrov AV, Mikulik R, Ribo M, Sharma VK, Lao AY, Tsivgoulis G, et al. A Pilot Randomized Clinical Safety Study of Thrombolysis Augmentation with Ultrasound-Activated Perflutren Lipid Microspheres. *Stroke* 2007;38:LBP4.

42. Perren F, Loulidi J, Poglia D, Landis T, Sztajzel R. Microbubble potentiated transcranial duplex ultrasound enhances IV thrombolysis in acute stroke. *Cerebrovasc Dis* 2007;23[epub ahead of print].

43. Larrue V, Viguier A, Arnaud C, Cognard C, Petit R, Rigal M, et al. Tran cranial Ultrasound Combined with Intravenous Microbubbles and Tissue Plasminogen Activator for Acute Ischemic Stroke: A Randomized Controlled Study Stroke 2007;38:472.

44. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. *Stroke* 1997;28:2109-2118.

45. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. For the second European-Australasian Acute Stroke Study investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). *Lancet* 1998;352:1245-1251.

46. http://www.imarx.com/ImaRx/clinical_trials5_0